interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Enasidenib Mesylate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Enasidenib Mesylate, and who makes it?

Enasidenib Mesylate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Enasidenib Mesylate1 dosage-form group in the Orange Book
0generic makers listed
  1. Enasidenib Mesylate appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Idhifa. No generic is listed as marketed.

2015202020252030203501brand 2017data datePatent 10610125 listed to expire 21 June 2030Patent 9512107 listed to expire 7 January 2033Patent 10294215 listed to expire 7 January 2033Patent 10093654 listed to expire 1 August 2034Patent 9738625 listed to expire 1 August 2034Patent 9732062 listed to expire 16 September 2034
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 21 June 2030Patent 10610125
  • 7 January 2033Patent 9512107 drug substance
  • 7 January 2033Patent 10294215 drug product
  • 1 August 2034Patent 10093654 drug substance
  • 1 August 2034Patent 9738625 drug substance
  • 16 September 2034Patent 9732062 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.